Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
|
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
    Wei, Shuli
    Hu, Mangsha
    Yang, Yan
    Huang, Xiaojie
    Li, Baizhou
    Ding, Liren
    Wang, Pingli
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
    Ryu, Woo Kyung
    Cha, Hyungkeun
    Park, Mi Hwa
    Kim, Jung Soo
    Choi, Jeong-Seok
    Kim, Lucia
    Lee, Kyung-Hee
    Nam, Hae-Seong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
    Tachi, Hiroaki
    Nishino, Kengo
    Nakaizumi, Taisuke
    Kuramoto, Kenya
    Shimizu, Kei
    Yamamoto, Yusuke
    Kobayashi, Keisuke
    Ichimura, Hideo
    Sakata, Akiko
    Nawa, Takeshi
    THORACIC CANCER, 2020, 11 (07) : 2063 - 2066
  • [34] Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC A case report
    Wang, Jinjing
    Luo, Shuai
    Li, Yao
    Zheng, Hong
    MEDICINE, 2021, 100 (03) : E24377
  • [35] Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
    Zhu, You-cai
    Lin, Xue-ping
    Li, Xiao-feng
    Wu, Li-xin
    Chen, Hua-fei
    Wang, Wen-xian
    Xu, Chun-wei
    Shen, Jian-fa
    Wei, Jian-guo
    Du, Kai-qi
    THORACIC CANCER, 2018, 9 (01) : 159 - 163
  • [36] EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
    Michels, Sebastian
    Gardizi, Masyar
    Schmalz, Petra
    Thurat, Meike
    Pereira, Eva
    Sebastian, Martin
    Carcereny, Enric
    Corral, Jesus
    Paz-Ares, Luis
    Felip, Enriqueta
    Grohe, Christian
    Rodriguez Abreu, Delvys
    Insa Molla, Amelia
    Bischoff, Helge
    Reck, Martin
    Karachaliou, Niki
    Scheel, Andreas
    Brandes, Vanessa
    Rieke, Fischer
    Nogova, Lucia
    Scheffler, Matthias
    Franklin, Jeremy
    Hellmich, Martin
    Massuti, Bartomeu
    Buettner, Reinhard
    Rosell, Rafael
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S379 - S380
  • [37] GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
    Zeng, Liang
    Yang, Nong
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E114 - E116
  • [38] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Ju, Lixia
    Han, Mingquan
    Su, Jinmei
    Wu, Chunyan
    Dong, Zhengwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 561 - 564
  • [39] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Lixia Ju
    Mingquan Han
    Jinmei Su
    Chunyan Wu
    Zhengwei Dong
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 561 - 564
  • [40] Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report
    Zhao, Shikang
    Zhu, Shuai
    Lei, Xi
    Xu, Dongbo
    Shi, Tao
    Chen, Qiusong
    Ren, Fan
    Chen, Gang
    Huang, Dingzhi
    Xu, Song
    THORACIC CANCER, 2021, 12 (20) : 2815 - 2818
12345